Recipharm AB - Company Profile
Powered by 
All the data and insights you need on Recipharm AB in one report.
$295
- Save hours of research time and resources with
our up-to-date Recipharm AB Strategy Report
- Understand Recipharm AB position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Recipharm AB (Recipharm) is a contract development and manufacturing organization (CDMO) that offers manufacturing, development and technology services. The company's manufacturing services include contract manufacturing of pharmaceuticals such as semi-solids, oral liquids, solid doses, and sterile products, besides clinical trial materials including APIs and other drugs. Recipharm’s development and technology services assist customers from the initial product concept to the approved commercial pharmaceutical drug. It includes services such as raw material supply, formulation, and validated analytical methods, among others. The company operates in the UK, Germany, Spain, Italy, Sweden, France, Portugal, India, Israel, and the US. Recipharm is headquartered in Stockholm, Sweden.
Headquarters
Sweden
Address
Box 603, Drottninggatan 29, Stockholm, SE-10132
Website
www.recipharm.com
Telephone
46 8 6025200
No of Employees
8,747
Industry
Pharmaceuticals and Healthcare
Revenue (2022)
$1.3B
Recipharm AB premium industry data and analytics
Products and Services
| Services |
|---|
| Pharmaceutical Development |
| API Development |
| Clinical Supply |
| XYZ |
| XYZ |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Contracts/Agreements | In December, the company entered into an agreement with Acuitas Therapeutics to facilitate rapid technological exchanges and CGMP production of Acuitas' LNP formulations. |
| 2023 | Contracts/Agreements | In September, the company partnered with Ahead Therapeutics to develop a ground-breaking treatment for a rare autoimmune disease, myasthenia gravis. |
| 2023 | Contracts/Agreements | In April, Arranta Bio signed a contract with MIT to develop a continuous manufacturing technology for mRNA therapeutics. |
Competitor Comparison
| Key Parameters | Recipharm AB | F. Hoffmann-La Roche Ltd | Catalent Inc | Iconovo AB | Corden Pharma International GmbH |
|---|---|---|---|---|---|
| Headquarters | Sweden | Switzerland | United States of America | Sweden | Switzerland |
| City | Stockholm | Basel | Somerset | Lund | Basel |
| State/Province | Stockholm | - | New Jersey | - | Basel-Stadt |
| No. of Employees | 8,747 | 103,605 | 17,800 | 32 | 2,600 |
| Entity Type | Private | Public | Public | Public | Private |
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Richard Ridinger | Chairman | Executive Board | 2021 | 65 |
| Greg Behar | Chief Executive Officer | Senior Management | 2024 | - |
| Joaquim Mascaro | Chief Financial Officer | Senior Management | 2023 | - |
| Luc Burgard | Chief Operating Officer | Senior Management | - | - |
| Christophe Lamacq | Chief Human Resources Officer | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer